The 8-week reduction in vasomotor symptom frequency from baseline relative to placebo was similar for escitalopram at -1.4 per day ( 95 % confidence interval [ CI ] -2.7 to -0.2 ) , low-dose E2 at -2.4 ( 95 % CI -3.4 to -1.3 ) , and venlafaxine at -1.8 ( 95 % CI -2.8 to -0.8 ) ; vasomotor symptom bother reduction was minimal and did not vary across these three pharmacologic interventions ( mean -0.2 to -0.3 relative to placebo ) .